Adaptimmune Therapeutics Introduces Breakthrough TECELRA® Cell Therapy for Solid Tumor
Adaptimmune Therapeutics has unveiled TECELRA® (afamitresgene autoleucel), a groundbreaking treatment for adults with unresectable or metastatic synovial sarcoma who have previously undergone chemotherapy.
TECELRA® (afamitresgene autoleucel) is a genetically modified autologous T cell immunotherapy targeting the melanoma-associated antigen A4 (MAGE-A4). It is designed for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A02:01P, -A02:02P, -A02:03P, or -A02:06P positive, and whose tumours express the MAGE-A4 antigen.
TECELRA (afami-cel) represents a significant advancement from current standards of care for advanced synovial sarcoma by leveraging each patient’s own immune cells to target and destroy cancer cells in a single infusion treatment.
Soft tissue sarcomas encompass more than 50 different types of tumours that can develop in fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. Synovial sarcoma accounts for about 5 to 10 percent of all soft tissue sarcomas, with approximately 13,400 new soft tissue cases diagnosed annually in the U.S.
The approval of TECELRA represents a major breakthrough in treatment options for synovial sarcoma patients and a significant milestone in the use of cell therapies for solid tumor cancers.
